Repare Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de Repare Therapeutics es Lloyd Segal , nombrado en Sep 2016, tiene una permanencia de 8.17 años. compensación anual total es $4.99M, compuesta por 12.3% salario y 87.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.28% de las acciones de la empresa, por valor de $331.21K. La antigüedad media del equipo directivo y de la junta directiva es de 5.5 años y 4.7 años, respectivamente.
Información clave
Lloyd Segal
Chief Executive Officer (CEO)
US$5.0m
Compensación total
| Porcentaje del salario del CEO | 12.3% |
| Permanencia del CEO | 8.2yrs |
| Participación del CEO | 0.3% |
| Permanencia media de la dirección | 5.5yrs |
| Promedio de permanencia en la Junta Directiva | 4.7yrs |
Actualizaciones recientes de la dirección
Recent updates
Analysts' Revenue Estimates For Repare Therapeutics Inc. (NASDAQ:RPTX) Are Surging Higher
Nov 13
There's No Escaping Repare Therapeutics Inc.'s (NASDAQ:RPTX) Muted Revenues Despite A 35% Share Price Rise
Oct 05Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data
Aug 30Will Repare Therapeutics (NASDAQ:RPTX) Spend Its Cash Wisely?
Jul 12Repare Therapeutics Inc.'s (NASDAQ:RPTX) 34% Dip In Price Shows Sentiment Is Matching Revenues
May 01Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 30% Plummet
Mar 12We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully
Feb 15Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Fly 30% But Investors Aren't Buying For Growth
Dec 20Here's Why We're Not At All Concerned With Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation
Oct 24New Forecasts: Here's What Analysts Think The Future Holds For Repare Therapeutics Inc. (NASDAQ:RPTX)
Aug 14Analysts Are Betting On Repare Therapeutics Inc. (NASDAQ:RPTX) With A Big Upgrade This Week
May 14Analysts Are Upgrading Repare Therapeutics Inc. (NASDAQ:RPTX) After Its Latest Results
May 12Repare Therapeutics Inc. (NASDAQ:RPTX) Looks Inexpensive But Perhaps Not Attractive Enough
May 08Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31%
Mar 03Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Oct 27Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma Partners
Sep 07Repare Therapeutics GAAP EPS of -$0.91 misses by $0.06, revenue of $0.67M
Aug 04Repare Therapeutics: Interesting Gene Editing Company, But Miles To Go
Jun 27Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Jun 24Repare Therapeutics (NASDAQ:RPTX) Is In A Good Position To Deliver On Growth Plans
Mar 02We're Not Worried About Repare Therapeutics' (NASDAQ:RPTX) Cash Burn
Oct 14We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth
Apr 16Have Repare Therapeutics Inc. (NASDAQ:RPTX) Insiders Been Selling Their Stock?
Mar 12Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$84m |
| Jun 30 2024 | n/a | n/a | -US$69m |
| Mar 31 2024 | n/a | n/a | -US$46m |
| Dec 31 2023 | US$5m | US$615k | -US$94m |
| Sep 30 2023 | n/a | n/a | -US$97m |
| Jun 30 2023 | n/a | n/a | -US$3m |
| Mar 31 2023 | n/a | n/a | -US$29m |
| Dec 31 2022 | US$4m | US$592k | -US$29m |
| Sep 30 2022 | n/a | n/a | -US$26m |
| Jun 30 2022 | n/a | n/a | -US$132m |
| Mar 31 2022 | n/a | n/a | -US$120m |
| Dec 31 2021 | US$4m | US$572k | -US$107m |
| Sep 30 2021 | n/a | n/a | -US$94m |
| Jun 30 2021 | n/a | n/a | -US$77m |
| Mar 31 2021 | n/a | n/a | -US$62m |
| Dec 31 2020 | US$5m | US$505k | -US$53m |
| Sep 30 2020 | n/a | n/a | -US$46m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$35m |
| Dec 31 2019 | US$2m | US$430k | -US$27m |
Compensación vs. Mercado: La compensación total de Lloyd($USD4.99M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD649.07K).
Compensación vs. Ingresos: La compensación de Lloyd ha aumentado mientras la empresa no es rentable.
CEO
Lloyd Segal (60 yo)
8.2yrs
Permanencia
US$4,991,804
Compensación
Mr. Lloyd Mitchell Segal serves as Director at HotKnot Therapeutics, Inc. Mr. Segal has been the Chief Executive Officer, President and Director of Repare Therapeutics Inc. since September 2016. Mr. Segal...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 8.2yrs | US$4.99m | 0.28% $ 331.2k | |
| Executive VP & CFO | 5.1yrs | US$1.93m | 0.034% $ 40.5k | |
| Executive VP & Chief Medical Officer | 5.5yrs | US$2.09m | 0.47% $ 561.4k | |
| Co-Founder | no data | sin datos | sin datos | |
| Co-Founder | no data | sin datos | sin datos | |
| Co-Founder | no data | sin datos | sin datos | |
| Executive VP & Chief Scientific Officer | 5.5yrs | US$1.83m | 0.098% $ 116.7k | |
| Executive Vice President of Human Resource | 1.5yrs | sin datos | 0.0037% $ 4.4k | |
| Executive Vice President of Discovery | 8.4yrs | sin datos | 0.055% $ 65.8k | |
| Executive VP | 2.8yrs | sin datos | 0.0092% $ 11.0k |
5.5yrs
Permanencia media
53yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de RPTX es experimentado (5.5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 8.2yrs | US$4.99m | 0.28% $ 331.2k | |
| Independent Director | 4.4yrs | US$274.74k | 0.0094% $ 11.2k | |
| Independent Director | 5.2yrs | US$265.41k | 0% $ 0 | |
| Independent Director | 1.4yrs | US$664.86k | 0% $ 0 | |
| Independent Director | less than a year | sin datos | sin datos | |
| Independent Director | 5yrs | US$265.31k | 0% $ 0 | |
| Independent Chairman | 3.2yrs | US$291.49k | 0.018% $ 21.1k | |
| Independent Director | 5.7yrs | US$272.99k | 0.019% $ 22.5k |
4.7yrs
Permanencia media
58yo
Promedio de edad
Junta con experiencia: La junta directiva de RPTX se considera experimentada (4.7 años de antigüedad promedio).